Operating cash flow of $37.0M in Q3 2026 ran about 1.65 times net income, though quarterly conversion has been highly volatile, with free cash flow margin swinging from 20.2% in Q2 2026 to 4.9% in Q3 2026 largely due to working capital swings.
LifeStance Health Group, Inc. (LFST) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | 227.6M | 146.15M | 107.26M | -16.88M | 52.79M | 9.42M | -8.53M | 17.05M |
| Operating CF Margin % | - | 10.26% | 8.57% | -1.6% | 6.14% | 1.41% | -2.26% | 8.02% |
| Operating CF Growth % | 1253.97% | 36.26% | 735.28% | -131.98% | 460.39% | 210.39% | -150.05% | - |
| Net Income | 71.91M | 9.66M | -57.44M | -186.26M | -215.56M | -307.2M | -38.07M | 5.67M |
| Depreciation & Amortization | 55.94M | 54.75M | 70.95M | 80.44M | 69.2M | 54.14M | 31.05M | 6.09M |
| Stock-Based Compensation | 69.82M | 74.7M | 76.17M | 99.39M | 187.43M | 259.44M | 1.45M | 54K |
| Deferred Taxes | 2.42M | 2.42M | -958K | -21.92M | -16.73M | -26.95M | 0 | 1.76M |
| Other Non-Cash Items | 49.3M | 44.96M | 45.91M | 45.2M | 45.4M | 27.85M | -2.21M | 478K |
| Working Capital Changes | -21.79M | -40.34M | -27.37M | -33.72M | -16.94M | 2.14M | -753K | 2.99M |
| Change in Receivables | 982K | 36.09M | -6.4M | -24.18M | -21.66M | -24.21M | -13.3M | -5.76M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -4.94M | -1.56M | 501K | -5.61M | 7.67M | 623K | 829K | 2.54M |
| Cash from Investing | -57.92M | -36.13M | -21.57M | -60.34M | -139.46M | -194.08M | -861.17M | -73.38M |
| Capital Expenditures | -12.2M | -36.13M | -21.57M | -40.52M | -79.25M | -94.49M | -38.07M | -14.31M |
| CapEx % of Revenue | 0.73% | 2.54% | 1.72% | 3.84% | 9.22% | 14.16% | 10.09% | 6.74% |
| Acquisitions | -9.59M | 0 | 0 | -19.82M | -60.21M | -99.58M | -823.1M | -59.06M |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -36.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -154.77M | -15.96M | -9.95M | 47.43M | 47.26M | 313.86M | 912.27M | 48.46M |
| Debt Issued (Net) | -12.69M | -7.25M | -1.69M | 55.28M | 69.56M | -223.77M | 291.41M | 55.45M |
| Equity Issued (Net) | -122.43M | 0 | 0 | 0 | -904K | 549.9M | 20M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -122.43M | 0 | 0 | 0 | -904K | 0 | -1M | 0 |
| Other Financing | -19.65M | -8.71M | -8.26M | -7.86M | -21.39M | -12.28M | 600.87M | -6.99M |
| Net Change in Cash | 14.91M | 94.07M | 75.75M | -29.8M | -39.41M | 129.2M | 15.35M | -7.86M |
| Free Cash Flow | 215.4M | 110.03M | 85.69M | -57.4M | -26.47M | -85.07M | -46.6M | 2.73M |
| FCF Margin % | 12.85% | 7.72% | 6.85% | -5.44% | -3.08% | -12.74% | -12.35% | 1.29% |
| FCF Growth % | 80.41% | 28.39% | 249.28% | -116.9% | 68.89% | -82.56% | -1804.43% | - |
| FCF per Share | 0.55 | 0.28 | 0.23 | -0.16 | -0.07 | -0.26 | -0.12 | 0.01 |
| FCF Conversion (FCF/Net Income) | 3.00x | 15.12x | -1.87x | 0.09x | -0.24x | -0.03x | 0.22x | 3.01x |
| Interest Paid | 12.3M | 17.8M | 24.99M | 21.04M | 14.37M | 22.41M | 0 | 4.58M |
| Taxes Paid | 1.29M | 1.57M | 57K | 80K | 2.24M | 1.09M | 0 | 254K |
Quick answers to the most common questions about buying LFST stock.
LifeStance Health Group, Inc. (LFST) generated $146.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
LifeStance Health Group, Inc. (LFST) generated $110.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
LifeStance Health Group, Inc. (LFST) spent $36.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Clinician retention and wage pressure
Metrics are mathematically derived from official filings.
Operating Cash Flow Diverges From Net Income
Based on reported quarterly figures, LFST's operating cash flow of $37.0M in Q3 2026 ran about 1.65 times net income of $22.4M, while Q2 2026 OCF reached 4.23 times net income, suggesting cash conversion is highly volatile quarter to quarter.
The gap between net income and operating cash flow is the central signal here, and the ratio swings sharply between quarters rather than converging toward a stable relationship. Much of this variance appears to be driven by working capital movements, which turned from a $47.0M drag in Q1 2025 to a $29.9M contribution in Q2 2026, indicating that reported profits are not translating into cash on a consistent basis. Investors should monitor whether collection timing and payor settlement patterns normalize, as the current pattern warrants further investigation rather than being treated as durable cash generation.
Free Cash Flow Turns Positive but Lumpy
According to the reported figures, LFST's free cash flow margin reached 20.2% in Q2 2026 and 21.7% in Q4 2025, yet fell to 4.9% in Q3 2026, indicating that cash generation has not yet established a steady run rate.
Free cash flow has been positive in most recent quarters, but the 2025 Q1 negative FCF of $10.3M and the sharp swings since then suggest that headline cash generation depends heavily on timing effects rather than purely on the underlying earnings base. Net income remained near breakeven across the period, so the bulk of FCF strength appears to come from working capital and non-cash add-backs, notably stock-based compensation of $18.2M to $19.7M per quarter. This implies that the true cash earnings power is more modest than the peak quarters suggest.
Light Capital Intensity Masks Center Investment
Based on LFST's reported capital expenditures, CapEx ran between 1.6% and 6.6% of revenue across recent quarters, with the Q4 2025 spike to $25.2M appearing to reflect a discrete build-out or lease-related outlay rather than routine maintenance.
Most quarters show capital spending near 2 to 3 percent of revenue, consistent with a low-intensity outpatient model where clinicians rather than equipment drive economics. The Q4 2025 positive CapEx entry is anomalous and may reflect a reclassification or timing item that warrants further investigation. Because D&A has run steadily between $13M and $15M per quarter, maintenance capital needs appear to be roughly covered, though the business does not appear to be generating large growth investment that would explain elevated capital outlays.
Working Capital Drives Quarterly Cash Swings
As reported in financial statements, LFST's working capital changes ranged from a $47.0M outflow in Q1 2025 to a $29.9M inflow in Q2 2026, indicating that receivables and payables timing dominates reported operating cash flow.
The magnitude of working capital swings relative to net income suggests that collections from payors and patients are the primary lever behind quarterly cash results rather than operating margin improvement. Given that management's revenue guidance depends on sustained payor collections, a reversal in working capital could compress cash flow quickly even if earnings hold. Investors should monitor receivable aging and implicit price concession trends to determine whether these inflows are sustainable.
Stock Compensation Flatters Reported Cash Flow
Based on reported figures, LFST's stock-based compensation of $19.7M in Q2 2026 is nearly equal to the period's net income of $23.6M, suggesting a substantial portion of apparent earnings quality rests on non-cash labor costs.
Because SBC is added back in operating cash flow, the cash profile may look stronger than the cash cost of attracting and retaining clinicians and executives would suggest. If equity compensation must be replaced with cash compensation to sustain clinician retention in a competitive wage market, free cash flow could be materially lower than current reported levels. This implies that the headline cash flow conversion may overstate the economic cash earnings available to shareholders.